> Details

Gálvez-Cárdenas, Kenny Mauricio; Enciso-Olivera, Leonardo José; Samanez-Figari, César Augusto; Quintana-Truyenque, Shirley; Castillo-Ríos, Benito Arturo; Quintero-Vega, Guillermo Enrique; Arrieta-López, Elizabeth; Pinto-Gómez, Alexis Javier; Aruachan-Vesga, Sandra; Durán-Sánchez, María Isabel; Espino-Lopéz, Germán

Treatment patterns and clinical outcomes in acute myeloid leukemia patients who are not eligible for intensive induction chemotherapy: A real-world study from Latin-America

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Treatment patterns and clinical outcomes in acute myeloid leukemia patients who are not eligible for intensive induction chemotherapy: A real-world study from Latin-America
  • Contributor: Gálvez-Cárdenas, Kenny Mauricio; Enciso-Olivera, Leonardo José; Samanez-Figari, César Augusto; Quintana-Truyenque, Shirley; Castillo-Ríos, Benito Arturo; Quintero-Vega, Guillermo Enrique; Arrieta-López, Elizabeth; Pinto-Gómez, Alexis Javier; Aruachan-Vesga, Sandra; Durán-Sánchez, María Isabel; Espino-Lopéz, Germán
  • Published: EDIMECO, 2023
  • Published in: Medicina y Laboratorio, 27 (2023) 4, Seite 315-332
  • Language: Not determined
  • DOI: 10.36384/01232576.683
  • ISSN: 2500-7106; 0123-2576
  • Keywords: General Arts and Humanities
  • Origination:
  • Footnote:
  • Description: Introduction. There is a knowledge gap concerning patients with acute myeloid leukemia (AML) who are not eligible for intensive induction chemotherapy; this, together with a recent increase in the incidence in Latin America, encloses a need. Through real-world evidence, we describe and compare the results of the different treatment strategies within this context. Methodology. This is a longitudinal, descriptive, retrospective study of a cohort of Latin American patients with AML not eligible for intensive induction chemotherapy, treated with low-intensity chemotherapy or with the best supportive care alone between January 1, 2015, to December 31, 2018. Results. Of a total of 125 patients (median age 74.8 years), the majority received low-intensity chemotherapy (78.4%). The median time in months of overall survival (9.2), progression-free survival (4.8), and time to treatment failure (3.8) were longer in patients receiving hypomethylating agents. Additionally, better results were observed with low-intensity chemotherapy (complete response 11.2% and stable disease 17.3%) compared to the best supportive care alone. Conclusion. We deliver a real-world standpoint of Latin American patients with AML who are not eligible for intensive induction chemotherapy. Our findings pave the first steps of the way to describe, understand, and support informed decision-making processes in our region.
  • Access State: Open Access